- "According to the report, approximately 20% of TB cases globally are estimated to be resistant to at least one of the first- or second-line anti-TB drugs, and 5% are resistant to both isoniazid and rifampicin, the most powerful and commonly used antibiotics in first-line treatment. Of the estimated 480,000 cases of multidrug-resistant (MDR) TB, approximately 10% are either extensively drug-resistant (XDR)—with additional resistance to second-line drugs—or totally drug resistant."
- "While TB is curable when patients adhere to the treatment regimen, MDR- and XDR-TB are more problematic. Treatment options are limited, expensive, and often toxic, and drug therapy can last up to 2 years. The report estimates mortality rates of around 40% for MDR-TB and 60% for XDR-TB. And while China, India, Russia, and South Africa have the highest burden of MDR- and XDR-TB, widespread international travel and migration means drug-resistant TB has no borders."
https://www.cidrap.umn.edu/antimicrobial-stewardship/report-... (2017)
If TB poses no risk because antibiotics are widely available would it not follow that reducing their availability would increase the risk TB poses?
The COVID 19 global pandemic was only a few years ago and its impacts lasted years. TB is not as infectious and would have a reduced spread but treating it helps contain possible issues and may one day lead to its eradication.
How does cutting funding reduce risk? Reduce suffering?